Pain management with non-steroidal antiinflammatory drugs (NSAIDs) like Naproxen when given orally causes gastrointestinal complications. This study developed and optimized a Chitosanpolylactic acid (PLA) nanocomposite transdermal patch for controlled delivery of Naproxen that not only increases bioavailability but also patient compliance to treatment. The patches synthesized using solvent evaporation method with different Chitosan concentrations (0-1.0% w/w) while incorporating 10% of Naproxen. FTIR, DSC, XRD, mechanical testing, swelling studies, and in vitro release of the composites with kinetic modeling were used to characterize the composites. The results showed that Chitosan acts as a reducing agent of the PLA crystallinity (from 35% to 15%) and also as a facilitator for the flexibility increase (elongation up to 15%) and swelling (up to 65%) enhancements. The upper limit of drug loading was more than 95% and the encapsulation efficiency was 90% in the optimized PCC-1.0, with the release being sustained (84.8% over 24 hours) following anomalous transport (n=0.68), and the burst effects being minimized in comparison with the controls (98.1% release). The above-mentioned properties are unequivocal evidence that extended analgesia can be provided without risking the GI tract. Also, the biodegradable, biocompatible patch not only places itself among the developments in TDDS for chronic pain but also offers a sustainable alternative to the painful and costly traditional methods. The next step involves conducting in vivo studies which will provide evidence of clinical efficacy